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Trans-cis Isomerization of Urocanic Acid in Response to Ultraviolet Light 
I To the Editor: 
I read with great interest the article on Cis-Urocanic Acid, by 
Noonan et ai, which reported that this chemical initiates an im-
tnune defect in animals. 
Trans-cis isomerization of urocanic acid in response to ultraviolet 
light was originally reported from our laboratory here at the Uni-
versity of Oklahoma in 1961 (Archives Derm 84:717 - 719, 1961) 
by our chief biochemist Dr. J. H. Anglin, J r. I feel certain that Dr. 
Anglin would have been greatly pleased to learn of this possibly 
significant role of a chemical which interested and perplexed him 
during a long and distinguished career as a dermatologic investiga-
tor. 
Mark Allen Everett, M.D. 
The University of Oklahoma Health Sciences Center 
Oklahoma City, OK 
Reply 
Weare pleased that Dr Everett has pointed out that Dr Anglin first 
described the trans-cis isomerization of urocanic acid (UCA) in skin 
by ultraviolet radiation. We were aware of Dr Anglin's work on 
UCA and had referenced two of his papers (although not the one 
referred to by Dr Everett) in our previous study, which put forward 
the hypothesis that trans UCA is the photoreceptor for UV -induced 
immunosuppression based on the detailed action spectrum for this 
effect (De Fabo and Noonan: J. Exp. Med. 185:84, 1983). We 
simply inadvertently omitted reference to Dr Anglin in the current 
study . The original papers by Anglin and Everett on UCA were of 
special importance to us. After completing our in vivo action spec-
trum after nearly 2 years of detailed optical and immunologic mea-
surements, we were in search of a compound with which to match 
it. The action spectrum did not match the absorption spectra of the 
major UV skin absorbers such as DNA, 7-dehydrocholesterol, or 
the amino acids tryptophane and tyrosine. Until we came upon the 
early articles on UCA, particularly those by Anglin and Everett and 
later by Baden and Pathak and more recently by Ian Scott, we were 
actively searching for a chromophore. Thus, these early papers were 
very helpful to us in proposing and testing our hypothesis that UCA 
does in fact interact with the immune system, bringing about an 
alteration in antigen-presenting cell activity with subsequent sup-
pressor T-cell formation. 
Frances Noonan, Ph.D. 
Edward De Fabo, Ph.D. 
The George Washington University Medical Center 
Washington, DC 
Is AL721 Really a Lipid Fluidity Modulating Agent? 
To the Editor: 
Immunoregulatory properties of lipids and especially the lipid flu-
idity of the lymphocyte plasma membrane have recently received 
increasing clinical attention [1 ,2]. 
With the purpose of investigating such phenomena the novel 
"fluidizing" lipid compound AL721 was introduced [3]. TIllS com-
mercially available agent is composed of neutral glycerides, phos-
phatidylcholine, and phosphatidylethanolamine in a ratio of7: 2: 1 
and has a purported abi lity to fluidize, i.e. , modulate, cellular mem-
branes by the elution of cholesterol. 
Based on reports indicating that the characteristically diminished 
irrlITIUne reponses in aging may be partially due to altered, i.e., rigid, 
lymphocyte plasma membranes, arising from an increased choles-
terol content [4], AL721 was first tested in clinical trials on healthy 
e lderly probands and was shown to enhance their in vitro lympho-
cyte proliferative capacity [5]. 
In the search for new therapeutic approaches for AIDS patients it 
'Was also speculated that it might be possible to influence HIV -in-
fectivity at the membranal level. One possibility envisaged was that 
modulation of their lipid environment might displace the mem-
brane receptors and thereby hinder virus-cell membrane interac-
tion. Recently it was demonstrated that AL721 is able to interfere 
'With HIV -infectivity and it is now being evaluated for the treatment 
of AIDS patients. 
A fluidizing effect of AL721 on either the lymphocyte plasma 
membrane or the viral surface membrane and concomitant alter-
ations of receptor or attachment protein exposition have been dis-
cussed as possible mechanist'ns of action [6,7]. However, in this 
letter we show that we do rIOt regard the listed effects of AL721 to be 
mediated by modulation of fluidity, at least in the case of lympho-
cytes. 
The fluidizing effect of AL721 was originally demonstrated by 
the fluorescence polarization technique using 1,6- diphenyl-1,3,5-
hexatriene (DPH) as a probe molecule [3] . Whereas we also ob-
served this modulating effect on human peripheral blood mononu-
clear cells (PBM; 70- 80% lymphocytes), we later showed that this 
so-called "fluidizing effect" was an artifact due to the uptake of 
AL721 by monocytes [8]. First, it was no longer seen when PBM 
were depleted of monocytes by a plastic-adherence step. Second, 
single cell DPH-polarization measurements in the flow cytometer 
showed that only the monocytes were affected. Third, sudan-black-
staining of AL721 pretreated PBM made strikingly clear that the 
monocytes were laden with lipids. This would lead to an artifact in 
fluidity measurements because it is well known that the DPH probe 
molecule does not remain confined to the plasma membrane but 
also stains intracellular membranes and lipid droplets [9] . To inves-
tigate for possible altered lymphocyte membrane properties that 
were not detectable by DPH-fluorescence polarization, we used 
two other techniques. We first used flow cytometric analysis to test 
the influence of AL721 on the expression of several lymphocyte 
surface markers, including CD-4, the receptor for HIV l10]; no 
AL721-induced changes of the expression of CD-4, CD-3, CD-8 
IL-2, or transferrin receptors on human lymphocytes could be de-
tected. We then analyzed AL721-pretreated lymphocytes by scan-
ning electron microscopy for differences in the form or density of 
surface microvilli; again no differences were found . 
In conclusion, there is no eIIidence that AL 721 exerts its effects by a 
so-called "fluidizing" modulation of plasma membranes (at least in 
the case oflymphocytes), and we advise against the assumption that 
AL721 is really an effective fluidizing agent. Other mechanisms of 
action should therefore be taken into account. 
Felix A. Offner, M.D. 
Karine N. Traill, Ph.D. 
Ute Winter, M.D. 
Georg Wick, M.D. 
U niversiry of Innsbruck 
Medical School, Austria 
